Exclusive Session on Pulmonary Embolism Banner

ACCESS PE SESSION REPLAY 

Master
Pulmonary Embolism
Save lives

'Enlighten your Academic Horizon for Pulmonary Embolism Treatment' Clot Club recording.

Transforming Pulmonary Embolism care: Insights from Global Experts 

Clot Club is a global educational series that connects healthcare professionals with leading experts in Pulmonary Embolism (PE). Each session delivers practical knowledge, clinical discussions, and frontline experiences in PE treatment.

This exclusive edition, moderated by Dr. Michael Jaff, explores the evolving landscape of PE care: current challenges, groundbreaking therapies, and the HI-PEITHO trial, a pivotal study that could reshape clinical guidelines for intermediate and high-risk patients.

Watch the full recording to gain game-changing insights from bold debates, real-world cases, and the latest evidence that could redefine PE treatment.

Session details

Speakers

 Andrew Sharp, MD

 Andrew
Sharp, MD

Stavros Konstantinides, MD​

Stavros Konstantinides, MD​

Nils Kucher, MD

Nils
Kucher, MD

Michael R. Jaff, DO

Michael R.
Jaff, DO

  • The limitations and challenges of current PE treatments.
  • How catheter-directed therapy (CDT) and ultrasound-assisted thrombolysis are redefining safety and precision.
  • The critical differences between HI-PEITHO and PEERLESS trials—and why they matter.
  • Expert insights into clinical deterioration, imaging for risk stratification, and preparing your center for the future of PE intervention.

Short on time? Skip to chapters highlights

1. Panel Overview 0:59
Welcome and session goals. Introduction of panelists

2. Introduction by Stavros Konstantinides 1:51
Current landscape of PE treatment and the importance of evidence-based approaches.

3. Panelist Introductions 03:03
Andrew Sharp and Niels Küker introduce themselves and their roles in PE research.

4. The Year of PE: A game-changer? By Andrew Sharp 05:01
Data on high-risk and intermediate-risk PE, the limitations of current treatments, and the potential of catheter-directed thrombolysis (CDT) with ultrasound-assisted devices.

5. Not all RCTs are the same: How is HI-PEITHO different from PEERLESS. By Nils Kucher 17:30
A comparison of trial designs, endpoints, and implications. The relevance of the HI-PEITHO trial, emphasizing its potential to shape future guidelines.

6. Panel Discussion and Audience Q&A 35:11
Interactive discussion on trial ethics, imaging, deterioration criteria, and treatment strategies.

7. Final Comments 54:50
Summary of key takeaways and closing remarks.

We’ve definitely got residual risk in this population—not just in the high-risk patients, the ones in shock, but in the intermediate high-risk who have got RV dysfunction and evidence of biomarker abnormality. And so, we clearly need something more. The question is, what should that be?

- Andrew Sharp on the limitations of current Pulmonary Embolism treatments and the need for innovation

icon-document-with-magnifying-glass

Discover more in our PE portal

Visit the PE portal
icon-person-with-headset

Talk to a sales rep

Request a rep

Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.